Glenmark Unveils Generic Sugammadex Injection in the U.S.

In July 2026, Glenmark Pharmaceuticals Inc. U.S. introduced Sugammadex injection, which is available in 200 mg/2 mL and 500 mg/5 mL single-dose vials. This drug is therapeutically equivalent to Merck Sharp & Dohme LLC’s BRIDION Injection (100mg/mL). Sugammadex injection is intended to be used for the reversal of neuromuscular blockade caused by rocuronium bromide and vecuronium bromide during surgery.

This launch is an important step forward for Glenmark in its future vision to expand its portfolio in the U.S. According to IQVIA, BRIDiON Injection achieved revenue of USD 1.6 billion from May 2025 to May 2026. According to Mark Kikuchi, the President and Business Head of Glenmark, North America, the first day of the launch shows the company’s agility and implementation capabilities.

Mark Kikuchi also said that this launch demonstrates the company’s commitment to making the supply chain reliable and improving access to drugs for patients. The company is committed to offering affordable drugs across the U.S. This launch shows the company’s vision to enhance its global business of injectables and improve its position in highly regulated sectors.

Impact on the Healthcare Industry

According to Precedence Research, the launch of the Sugammadex injection in the U.S. is expected to positively impact the healthcare industry as it helps patients receive affordable treatment for neuromuscular blockade. This launch comes at a time when the prevalence of chronic diseases in the U.S. is increasing, which leads to more admissions to the hospital and more surgeries. This results in more demand for the Sugammadex injection, which is required to reverse neuromuscular blockade during surgery. It is a generic injection and much more affordable than the BRIDION Injection. The cost factor is important as the cost of living has risen sharply in the U.S., and financial strain among the people is increasing continuously.

Impact on the Drug Formulation Market

The global drug formulation market size is calculated at USD 1.96 trillion in 2025 and is predicted to increase from USD 2.08 trillion in 2026 to approximately USD 3.50 trillion by 2035, expanding at a CAGR of 5.97% from 2026 to 2035.

According to Precedence Research, the introduction of the Sugammadex injection by Glenmark Inc. in the U.S. is expected to benefit the drug formulation market. This is because it propels the trend of more and more research for the development of affordable drugs, which are currently expensive and not accessible to many economic factions of society.

Such developments help the company to boost its reputation and revenue as its drugs reach more and more people. It will encourage other pharmaceutical companies to actively invest in their research and development programs to develop such generic drugs and gain significant market share.

Impact on the Generic Drugs Market

The global generic drugs market size is calculated at USD 468.08 billion in 2025 and is predicted to increase from USD 491.67 billion in 2026 to approximately USD 762.48 billion by 2035, expanding at a CAGR of 5% from 2026 to 2035.

According to Precedence Research, the generic drugs market is expected to be positively impacted by the launch of the Sugammadex injection, as it is a generic drug and more affordable than the BRIDION Injection. The usage of advanced automation technologies is decreasing the timeline of clinical trials for generic drugs, as AI models can test a huge number of biomarkers in a short period of time.

Digital health devices also aid the recruitment of participants from remote areas and even allow clinical trials to be conducted without the patients having to actually visit the company’s testing site. This allows even mid-sized pharmaceutical and biotechnology companies to compete with large corporations in developing generic drugs, resulting in a significant rise in the competition. Such conditions drive investment in research and development of better quality and lower cost to gain adoption among patients.

About Glenmark Inc.

Glenmark Pharmaceuticals is a prominent global healthcare solutions company that is committed to benefiting society by providing innovative medical products for patients. The company focuses on current diseases and conditions affecting people as well as keeps an eye on future illness possibilities. Glenmark concentrates on providing cures, building resilience in its customers, increasing life expectancy, and building a healthier future.

Glenmark has the vision to provide innovative drug therapies and make them accessible to a wide section of society. The company has significant experience in developing treatments in various medical departments, including oncology, dermatology, and respiratory diseases. Glenmark has a wide and diverse portfolio that spans multiple illnesses and includes branded, specialty, generics, and consumer categories. The company has a robust research and development and manufacturing infrastructure, which includes:

• 4 advanced research and development sites.
• 11 next-generation manufacturing facilities.

Glenmark has significant market share in various regions such as the U.S., Europe, Latin America, Asia Pacific, the Middle East, and Africa.